Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brexpiprazole for Agitation in Alzheimer's Dementia
NCT01862640Phase 3Completed
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- Jul 2013
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of brexpiprazole orally disintegrating tablet in Alzheimer's disease (AD) (3 arms), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Change From Baseline In The Cohen-Mansfield Agitation Inventory (CMAI) Total Score at 12 weeks. Started Jul 2013; status: completed.
02
Drugs
brexpiprazole orally disintegrating tablet
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT01862640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01862640.